BPTF and neoplasm: Moreover, lumbrokinase was found to inhibit tumor angiogenesis and sensitize NSCLC cells to bevacizumab via the targeted down-regulation of BPTF, weakening the binding of BPTF to the VEGF promoter, thereby decreasing the expression of VEGF.